Reported Sunday, KIMMTRAK Five-Year Phase 3 Data Shows Doubled Survival Likelihood Versus Investigator's Choice With Median OS Of 21.6 Months Versus 16.9 Months In Metastatic Uveal Melanoma
Benzinga Newsdesk 6 months ago
News
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaOS benefit observed across key subgroups, including patients with high tumor burden,
- KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
- OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease
- This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor